Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
The CRISPR therapy, SNIPR001, was administered following a single-patient emergency investigational new drug application.
Cytiva Navigating cell therapy WP 4
Rocket points to Danon gene therapy’s safety after Phase II protocol change
Estrella activates new site in Texas for STARLIGHT-1 Phase I/II trial
First patient treated in fifth cohort of Anixa’s ovarian cancer trial
EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML
ASCO26: In vivo oncology approaches continue to show promise
Framework launched to strengthen CGT trials in UK
REGENXBIO to push for accelerated approval of DMD gene therapy
